← Back to Search

Bronchodilator

Revefenacin for Chronic Obstructive Pulmonary Disease (PIFR-2 Trial)

Phase 4
Waitlist Available
Research Sponsored by Theravance Biopharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 30 through day 85
Awards & highlights

PIFR-2 Trial Summary

Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease

PIFR-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 30 through day 85
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 30 through day 85 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
80-mL improvement in trough FEV1
FEV1
FVC
+2 more

PIFR-2 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: RevefenacinExperimental Treatment2 Interventions
Revefenacin DoseA administered with tiotropium placebo
Group II: TiotropiumActive Control2 Interventions
Tiotropium DoseB administered with revefenacin placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Revefenacin
2022
Completed Phase 4
~740
Tiotropium Placebo
2022
Completed Phase 4
~410

Find a Location

Who is running the clinical trial?

Viatris Inc.Industry Sponsor
7 Previous Clinical Trials
4,494 Total Patients Enrolled
Theravance BiopharmaLead Sponsor
73 Previous Clinical Trials
8,215 Total Patients Enrolled
Mylan Inc.Industry Sponsor
62 Previous Clinical Trials
20,309 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Connecticut
Texas
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
2022. "Phase 4 COPD and Suboptimal Inspiratory Flow Rate". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05165485.
~124 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top